Results 21 to 30 of about 442,994 (306)

Clinical significance of Interleukin 17 receptor E in diabetic nephropathy

open access: yesInternational Immunopharmacology, 2023
Diabetic nephropathy (DN) is a leading cause of end-stage renal disease. Since there are limited therapeutic options available for the prevention of DN progression, it is imperative to explore novel differentially expressed genes and therapeutic targets for DN.In this study, mice kidney tissue were subjected to transcriptome sequencing and the results ...
Jingjing Wang   +5 more
openaire   +2 more sources

TRAF Regulation of IL-17 Cytokine Signaling

open access: yesFrontiers in Immunology, 2019
Tumor necrosis factor receptor (TNFR)-associated factors or (TRAFs) are important mediators of Interleukin-17 (IL-17) cytokine signaling and contribute to driving tissue responses that are crucial for protective immunity but are often implicated in ...
Shadi Swaidani   +5 more
doaj   +1 more source

Association of a non-synonymous SNP of IL17RA gene with litter size traits in Large White and Landrace pigs

open access: yesVeterinary Integrative Sciences, 2021
Interleukin-17 receptor A (IL17RA) is one of the cytokine receptors of the pro-inflammatory interleukin-17 (IL17) cytokine family. The IL17 and IL17RA genes are involved in inflammatory and immune responses as well as reproductive process of ...
Worrarak Norseeda   +6 more
doaj   +1 more source

Cutting Edge: Interleukin 17 Signals through a Heteromeric Receptor Complex [PDF]

open access: yesThe Journal of Immunology, 2006
AbstractIL-17 is an inflammatory cytokine produced primarily by a unique lineage of CD4 T cells that plays critical roles in the pathogenesis of multiple autoimmune diseases. IL-17RA is a ubiquitously expressed receptor that is essential for IL-17 biologic activity.
Dean, Toy   +7 more
openaire   +2 more sources

Essential role of NK cells in IgG therapy for experimental autoimmune encephalomyelitis.

open access: yesPLoS ONE, 2013
Intravenous immunoglobulin has long been used in treating autoimmune diseases, although mechanisms remain uncertain. Activating Fcγ receptors are receptors of IgG and reported to be essential in intravenous immunoglobulin (IVIG) therapy.
Wai Po Chong   +7 more
doaj   +1 more source

Dexmedetomidine attenuates oxygen-glucose deprivation/ reperfusion-induced inflammation through the miR-17-5p/ TLR4/ NF-κB axis

open access: yesBMC Anesthesiology, 2022
Background Dexmedetomidine (DEX) is a selective agonist of α2-adrenergic receptors with anesthetic activity and neuroprotective benefits. However, its mechanism of action at the molecular level remains poorly defined.
Liangyuan Suo, Mingyu Wang
doaj   +1 more source

The IL-17 family in diseases: from bench to bedside

open access: yesSignal Transduction and Targeted Therapy, 2023
The interleukin-17 (IL-17) family comprises six members (IL-17A–17F), and recently, all of its related receptors have been discovered. IL-17 was first discovered approximately 30 years ago.
Longjie Huangfu   +3 more
doaj   +1 more source

Interleukin-17 as a potential therapeutic target for chronic pain

open access: yesFrontiers in Immunology, 2022
Chronic pain remains to be a clinical challenge and is recognized as a major health problem with varying impacts on quality of life. Currently, the first-line therapy for chronic pain is opioids, which are often accompanied by unwanted psychoactive side ...
Xiaojuan Jiang   +11 more
doaj   +1 more source

Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease [PDF]

open access: yes, 2009
Traditionally, Crohn's disease has been associated with a Th1 cytokine profile, while Th2 cytokines are modulators of ulcerative colitis. This concept has been challenged by the description of tolerising regulatory T cells (Treg) and by proinflammatory ...
Brand, Stephan
core   +1 more source

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. [PDF]

open access: yes, 2015
Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists.
Biassoni   +67 more
core   +1 more source

Home - About - Disclaimer - Privacy